Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 03 tags : Phase 3 save search
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid TumorsMerus’ Fourth Sponsored Bispecific Antibody Currently in Clinical Trials
Published: 2021-05-03 (Crawled : 21:00) - biospace.com/
MRUS | $40.45 1.61% 1.55% 710K
|
Health Technology
|
| O: -0.29%
H: 9.87%
C: 9.1%
lung cancer solid tumors clinical trials phase 1 cancer antibody trial phase 3
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
Published: 2021-05-03 (Crawled : 21:00) - biospace.com/
ARQT | $8.94 -1.76% -1.9% 1M
|
Health Technology
|
| O: 5.31%
H: 0.6%
C: -1.5%
europe phase 3 symposium
Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes
Published: 2021-05-03 (Crawled : 18:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 0.55%
H: 1.25%
C: -0.69%
diabetes treatment hypoglycemia phase 3 trial
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
Published: 2021-05-03 (Crawled : 14:00) - biospace.com/
GLMD | $0.3641 -2.33% -0.41% 64K
|
Health Technology
|
| O: 1.23%
H: 3.55%
C: -0.91%
treatment fibrosis china phase 3 nash approval application aramchol
Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2021-05-03 (Crawled : 13:15) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 2.19%
H: 2.86%
C: -8.57%
molluscum treatment phase 3
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
Published: 2021-05-03 (Crawled : 13:00) - globenewswire.com
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 3.66%
H: 0.11%
C: -6.04%
presentation ongoing phase 1 trial phase 3 phase 2
Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil
Published: 2021-05-03 (Crawled : 13:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 0.82%
H: 5.78%
C: 1.4%
covid biopharma brazil phase 3
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Published: 2021-05-03 (Crawled : 12:57) - prnewswire.com
NVAX | $4.07 2.52% 2.93% 1.8M
|
Health Technology
|
| O: 0.66%
H: 0.54%
C: -18.19%
covid expansion vaccine phase 3 trial covid-19
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
RPTX 4 | $3.26 3.49% 2.48% 110K
|
Health Technology
|
| O: -0.52%
H: 1.75%
C: 0.4%
phase 1 trial phase 3 phase 2
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
XOMA | $25.61 0.51% 0.51% 7.2K
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: -3.47%
phase 3 milestone
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
Published: 2021-05-03 (Crawled : 12:00) - biospace.com/
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -4.18%
H: 1.62%
C: 1.41%
ALNY | $145.79 0.96% 0.94% 400K
|
Health Technology
|
| O: -0.11%
H: 0.09%
C: -3.66%
positive results phase 3
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.